AZAM KAZEMI, SAEİD ABROUN, MASOUD SOLEIMANI
Turkish Journal of Oncology - 2021;36(1):32-41
OBJECTIVE Apoptosis is considered the main factor inducing by bortezomib in myeloma cells. Although bortezomib (BTZ) is a crucial drug for the treatment of MM, chemoresistance is a major problem. OncomiR- 19a plays an oncogenic role in many types of cancer such as MM; however, the function of miR-19a in the pathogenesis of MM and drug resistance has not been identified well. The present research aims at investigating the inhibition of miR-19a by antagomir to conclude BTZ responsiveness and suggests that miR-19a may be a biomarker for the prognosis of the patient. METHODS In the present research, the viability and apoptosis of myeloma cells were analyzed by colorimetric MTT and Annexin-PI flow cytometric assays. QRT-PCR was implemented to evaluate the expression level of miR-19a, its targets SOCS3 and STAT3, at the mRNA level. RESULTS Following treating transfected cells with bortezomib we found out that miR-19a was downregulated, and the rate of apoptosis of myeloma cells after bortezomib treatment considerably increased. It indicated that mRNA of SOCS3 increased and STAT3 decreased. CONCLUSION The research results indicate that oncomiR-19a as a biomarker may induce better responsiveness to bortezomib in myeloma cell lines through its targets SOCS3, STAT3, and may provide new therapeutic targets in the future for myeloma. The research results indicate that oncomiR-19a as a biomarker may induce better responsiveness to bortezomib in myeloma cell lines through its targets SOCS3, STAT3 and may provide new therapeutic targets in the future for myeloma.
